Pharmaceutical companies IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma, Wockhardt, Lupin, Divi's, Zydus, Torrent, JB Chem, Glenmark, and Ajanta have surged to their highest levels in the past year. Other notable gains were seen among stocks like these.

Experts suggest Bharti Airtel, VBL, and PB Fintech as potential stocks for immediate profits due to their bullish trends. Meanwhile, IPCA Labs and Laurus Labs display robust upward trends, making them attractive for short-term investments as well.

IPCA Labs completed a significant block deal on the NSE, selling 103,156 shares for approximately INR 16 crore, with each share priced at INR 1,555.70.

The US tariff threat on certain medicines has caused Indian pharma stocks to decline, with notable drops seen in Biocon, Sun Pharma, Glenmark, Aurobindo, and Ipca Labs by 4-5%. The Nifty Pharma index fell by 3.8% due to these concerns about reshoring production.

Motilal Oswal's Sneha Poddar suggests investing in five stocks, such as ICICI Bank, Max Financial, Tata Power, Aurobindo Pharma, and IPCA Labs, due to their promising upside potential of up to 48%. These selections are driven by their strong growth, profitability, and operational enhancements.

Ipca Labs' stock appears to be gaining momentum, with strong technical signals suggesting a shift towards a bullish trend. Key metrics such as moving averages, Bollinger Bands, and MACD are all pointing positively, indicating potential growth in the near future.